M
Maria Banzi
Researcher at Academy for Urban School Leadership
Publications - 51
Citations - 1411
Maria Banzi is an academic researcher from Academy for Urban School Leadership. The author has contributed to research in topics: Colorectal cancer & Oxaliplatin. The author has an hindex of 14, co-authored 44 publications receiving 1013 citations. Previous affiliations of Maria Banzi include Mario Negri Institute for Pharmacological Research.
Papers
More filters
Journal ArticleDOI
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Thierry André,Armand de Gramont,Dewi Vernerey,Benoist Chibaudel,Franck Bonnetain,Annemilaï Tijeras-Raballand,Aurelie Scriva,Tamas Hickish,Josep Tabernero,Jean-Luc Van Laethem,Maria Banzi,E. Maartense,Einat Shacham Shmueli,Göran Carlsson,Werner Scheithauer,Demetris Papamichael,Marcus Möehler,Stefania Landolfi,Pieter Demetter,Soudhir Colote,Christophe Tournigand,Christophe Louvet,Alex Duval,Jean François Fléjou,Aimery de Gramont +24 more
TL;DR: The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer, and updated results support the use of FOLFOX in Patients with stage III disease, including those with dMMR or BRAF mutation.
Journal ArticleDOI
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini,Carlotta Antoniotti,Daniele Rossini,Sara Lonardi,Fotios Loupakis,Filippo Pietrantonio,Roberto Bordonaro,Tiziana Latiano,Emiliano Tamburini,Daniele Santini,Alessandro Passardi,Federica Marmorino,Roberta Grande,Giuseppe Aprile,Alberto Zaniboni,Sabina Murgioni,Cristina Granetto,Angela Buonadonna,Roberto Moretto,Salvatore Corallo,Stefano Cordio,Lorenzo Antonuzzo,Gianluca Tomasello,Gianluca Masi,Monica Ronzoni,Samantha Di Donato,Chiara Carlomagno,Matteo Clavarezza,Giuliana Ritorto,Andrea Mambrini,Mario Roselli,Samanta Cupini,Serafina Mammoliti,Elisabetta Fenocchio,Enrichetta Corgna,Vittorina Zagonel,Gabriella Fontanini,Clara Ugolini,Luca Boni,Alfredo Falcone,Filippo de Braud,Evaristo Maiello,Giovanni Luca Frassineti,Teresa Gamucci,Francesco Di Costanzo,Luca Gianni,Patrizia Racca,Giacomo Allegrini,Alberto Sobrero,Massimo Aglietta,Enrico Cortesi,Domenico Corsi,Alberto Ballestrero,Andrea Bonetti,Francesco Di Clemente,Enzo Maria Ruggeri,Fortunato Ciardiello,Marco Benasso,Stefano Vitello,Saverio Cinieri,Stefania Mosconi,Nicola Silvestris,Antonio Frassoldati,Samantha Cupini,Alessandro Bertolini,Giampaolo Tortora,Carmelo Bengala,Daris Ferrari,Antonia Ardizzoia,Carlo Milandri,Silvana Chiara,Gianpiero Romano,Stefania Miraglia,Laura Scaltriti,Francesca Pucci,Livio Blasi,Silvia Brugnatelli,Luisa Fioretto,A.S. Ribecco,Raffaella Longarini,Michela Frisinghelli,Maria Banzi +81 more
TL;DR: The triplet FOLFOXIRI showed improved outcomes for patients with metastatic colorectal cancer, compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab, but the actual benefit of the upfront exposure to the three cytotoxic drugs compared with a preplanned sequential strategy of doublets was not clear.
Journal ArticleDOI
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
T. Pressiani,Corrado Boni,Lorenza Rimassa,R. Labianca,Stefano Fagiuoli,Stefania Salvagni,Daris Ferrari,Enrico Cortesi,Camillo Porta,Claudia Mucciarini,L. Latini,C. Carnaghi,Maria Banzi,Silvia Fanello,M. De Giorgio,Fabio Romano Lutman,Guido Torzilli,M. A. Tommasini,R. Ceriani,Giovanni Covini,Maria Chiara Tronconi,Laura Giordano,N. Locopo,S. Naimo,Armando Santoro +24 more
TL;DR: Data suggest that patients with CP class B liver function can tolerate treatment and may still benefit from sorafenib, although patients with HCC and CP class A liver function have poorer outcomes than those withCP class A function.
Journal ArticleDOI
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Eric Van Cutsem,Erika Martinelli,Stefano Cascinu,Alberto Sobrero,Maria Banzi,Jean Francois Seitz,Carlo Barone,Marc Ychou,Marc Peeters,Baruch Brenner,Baruch Brenner,Ralf Hofheinz,Evaristo Maiello,Thierry André,Andrea Spallanzani,Rocio Garcia-Carbonero,Yull Edwin Arriaga,Udit Verma,Axel Grothey,Christian Kappeler,Ashok Miriyala,Joachim Kalmus,Alfredo Falcone,Alberto Zaniboni +23 more
TL;DR: The CONSIGN trial confirmed the safety profile of regorafenib from the phase III trials and reinforced the importance of using treatment modifications to manage adverse events.
Journal ArticleDOI
Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: Report of a case and review of the literature with demonstration of genes alteration into the same tumor cells
TL;DR: A case of pulmonary adenocarcinoma with concomitant EGFR mutation in exon 21 (L858R) and ALK rearrangement in naive and relapsed tumors is reported, and a speculative discussion on molecular mechanisms underlying this uncommon phenomenon and practical points about epidemiologic, clinicopathologic features and therapeutic options are reported.